Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Sitravatinib in locally advanced unresectable NSCLC
NCT05176925Phase 2Terminated
- Sponsor
- Fudan University
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sitravatinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Started Jan 2021; status: terminated.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05176925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176925.